A Novel Live-Attenuated Vaccine Candidate for Mayaro Fever

William J. Weise; Meghan E. Hermance; Naomi Forrester; A. Paige Adams; Rose Langsjoen; Rodion Gorchakov; Eryu Wang; Maria D.H. Alcorn; Konstantin Tsetsarkin; Scott C. Weaver

doi:10.1371/journal.pntd.0002969

A Novel Live-Attenuated Vaccine Candidate for Mayaro Fever

William J. Weise, Meghan E. Hermance, Naomi Forrester, A. Paige Adams, Rose Langsjoen, Rodion Gorchakov, Eryu Wang, Maria D.H. Alcorn, Konstantin Tsetsarkin, Scott C. Weaver

Microbiology And Immunology

Research output: Contribution to journal › Article › peer-review

34 Scopus citations

Abstract

Mayaro virus (MAYV) is an emerging, mosquito-borne alphavirus that causes a dengue-like illness in many regions of South America, and which has the potential to urbanize. Because no specific treatment or vaccine is available for MAYV infection, we capitalized on an IRES-based approach to develop a live-attenuated MAYV vaccine candidate. Testing in infant, immunocompetent as well as interferon receptor-deficient mice demonstrated a high degree of attenuation, strong induction of neutralizing antibodies, and efficacy against lethal challenge. This vaccine strain was also unable to infect mosquito cells, a major safety feature for a live vaccine derived from a mosquito-borne virus. Further preclinical development of this vaccine candidate is warranted to protect against this important emerging disease.

Original language	English (US)
Article number	e2969
Journal	PLoS neglected tropical diseases
Volume	8
Issue number	8
DOIs	https://doi.org/10.1371/journal.pntd.0002969
State	Published - Aug 7 2014

ASJC Scopus subject areas

Public Health, Environmental and Occupational Health
Infectious Diseases

Access to Document

10.1371/journal.pntd.0002969

Cite this

@article{0d9c7785dbf34d18b9f4cd66b1d0e737,

title = "A Novel Live-Attenuated Vaccine Candidate for Mayaro Fever",

abstract = "Mayaro virus (MAYV) is an emerging, mosquito-borne alphavirus that causes a dengue-like illness in many regions of South America, and which has the potential to urbanize. Because no specific treatment or vaccine is available for MAYV infection, we capitalized on an IRES-based approach to develop a live-attenuated MAYV vaccine candidate. Testing in infant, immunocompetent as well as interferon receptor-deficient mice demonstrated a high degree of attenuation, strong induction of neutralizing antibodies, and efficacy against lethal challenge. This vaccine strain was also unable to infect mosquito cells, a major safety feature for a live vaccine derived from a mosquito-borne virus. Further preclinical development of this vaccine candidate is warranted to protect against this important emerging disease.",

author = "Weise, {William J.} and Hermance, {Meghan E.} and Naomi Forrester and Adams, {A. Paige} and Rose Langsjoen and Rodion Gorchakov and Eryu Wang and Alcorn, {Maria D.H.} and Konstantin Tsetsarkin and Weaver, {Scott C.}",

note = "Publisher Copyright: {\textcopyright} 2014 Weise et al.",

year = "2014",

month = aug,

day = "7",

doi = "10.1371/journal.pntd.0002969",

language = "English (US)",

volume = "8",

journal = "PLoS neglected tropical diseases",

issn = "1935-2727",

publisher = "Public Library of Science",

number = "8",

}

TY - JOUR

T1 - A Novel Live-Attenuated Vaccine Candidate for Mayaro Fever

AU - Weise, William J.

AU - Hermance, Meghan E.

AU - Forrester, Naomi

AU - Adams, A. Paige

AU - Langsjoen, Rose

AU - Gorchakov, Rodion

AU - Wang, Eryu

AU - Alcorn, Maria D.H.

AU - Tsetsarkin, Konstantin

AU - Weaver, Scott C.

PY - 2014/8/7

Y1 - 2014/8/7

N2 - Mayaro virus (MAYV) is an emerging, mosquito-borne alphavirus that causes a dengue-like illness in many regions of South America, and which has the potential to urbanize. Because no specific treatment or vaccine is available for MAYV infection, we capitalized on an IRES-based approach to develop a live-attenuated MAYV vaccine candidate. Testing in infant, immunocompetent as well as interferon receptor-deficient mice demonstrated a high degree of attenuation, strong induction of neutralizing antibodies, and efficacy against lethal challenge. This vaccine strain was also unable to infect mosquito cells, a major safety feature for a live vaccine derived from a mosquito-borne virus. Further preclinical development of this vaccine candidate is warranted to protect against this important emerging disease.

AB - Mayaro virus (MAYV) is an emerging, mosquito-borne alphavirus that causes a dengue-like illness in many regions of South America, and which has the potential to urbanize. Because no specific treatment or vaccine is available for MAYV infection, we capitalized on an IRES-based approach to develop a live-attenuated MAYV vaccine candidate. Testing in infant, immunocompetent as well as interferon receptor-deficient mice demonstrated a high degree of attenuation, strong induction of neutralizing antibodies, and efficacy against lethal challenge. This vaccine strain was also unable to infect mosquito cells, a major safety feature for a live vaccine derived from a mosquito-borne virus. Further preclinical development of this vaccine candidate is warranted to protect against this important emerging disease.

UR - http://www.scopus.com/inward/record.url?scp=84921713602&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84921713602&partnerID=8YFLogxK

U2 - 10.1371/journal.pntd.0002969

DO - 10.1371/journal.pntd.0002969

M3 - Article

C2 - 25101995

AN - SCOPUS:84921713602

SN - 1935-2727

VL - 8

JO - PLoS neglected tropical diseases

JF - PLoS neglected tropical diseases

IS - 8

M1 - e2969

ER -

A Novel Live-Attenuated Vaccine Candidate for Mayaro Fever

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this